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Summary
T cell-specific expression of the human T cell receptor a (TCRa) gene is regulated by the
interaction of variable region promoter elements with a transcriptional enhancer that is located
4.5 kb 3' of the TCRa constant region (Cat) gene segment. The minimal TCRa enhancer
is composed of two nuclear protein binding sites, Toil and Ta2, that are both required for the
T cell-specific activity of the enhancer. The Tat binding site contains a consensus cAMP response
element (CRE), and binds a set of ubiquitous nuclear proteins. The Ta2 binding site does not
contain known transcriptional enhancer motifs. However, it binds at least two nuclear protein
complexes, one ofwhich is T cell specific. We now report that although the Ta2 nuclear protein
binding site displays transcriptional activator activity in the context of the TCR-a enhancer,
this site alone can function as a potent, T cell-specific transcriptional repressor when positioned
either upstream, or downstreamof several heterologous promoter and enhancer elements. These
results demonstrate that a single nuclear protein binding site can function as a T cell-specific
transcriptional activator or repressor element, depending upon the context in which it is located.
T
he process ofeukaryotic development involves the tissue-
specific and temporally regulated expression of specific
subsets of genes. The molecular mechanisms that positively
and negatively regulate gene expression during mammalian
development are complex, and involve the interaction ofubiq-
uitous, and tissue-specific nuclear proteins with cis-acting tran-
scriptional regulatory sequences known as promoter, enhancer,
and silencer elements (1-3) . Mammalian T lymphocyte de-
velopment in the thymus is an excellent model system for
studies designed to better elucidate the molecular mechanisms
that control developmentally regulated gene expression. Two
subsets of mammalian T cells have been identified that are
distinguished by theircell surface expression of heterodimeric
antigen receptor molecules (4, 5). All cells of the helper and
cytotoxic phenotype express the TCRo/omolecule, whereas
a second set of T cells, of unknown function, express the
related, but distinct TCR-,y/& These two T cell subsets ap-
pear to belong to separate developmental lineages, in that the
TCR-a gene is rearranged and expressed only in TCR-
a/(3+ cells, whereas the TCR6 gene is rearranged and ex-
pressed exclusively in TCR-,y/6' cells (5).
To better understand the molecular mechanisms that regu-
late the development of these two T cell subsets, we have
attempted to delineate the cis-actingsequences and trans-acting
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factors that control the rearrangement and expression of the
TCR genes. Previous studies havedemonstrated that human
and murine TCRa gene expression is regulated by a tran-
scriptional enhancer located 3-4.5 kb 3' of the single TCRa
Ca gene segment (6, 7). This enhancer is required for high
level transcription from a TCR Va promoter, and is active
only in TCR-a/0+ T cells (7). Deletion and in vitro muta-
genesis analyses, along with DNasel footprint experiments,
demonstrated that the minimal TCR-a enhancer is composed
oftwo nuclear protein binding sites, Toil and Ta2, that must
be separated by more than 15, and less than 85 nucleotides
(7, 8). The Tal binding site contains a consensus cAMP re-
sponse element (CRE),' and has been shown to bind a set
of ubiquitously expressed CRE binding proteins (CREBs).
In contrast, the Ta2 binding site does not contain previously
identified transcriptional enhancer motifs. However, it binds
at least two nuclear protein complexes, one of which is T
cell specific (8). In the studies described in this paper, we
demonstrate that the Ta2 nuclear protein binding site can
function as both a T cell-specific transcriptional activator and
repressor, depending upon the context in which it is located.
' Abbreviations used in this paper. CAT, chloroamphenicol acetyl transferase;
CRE, consensus cAMP response element; CREB, CRE binding protein.
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context ofthe intact TCRa enhancer. However, this binding
site, alone functions as a T cell-specific transcriptionalrepressor
when positioned either upstream or downstream of a variety
of heterologous promoter and enhancer elements. To our
knowledge, this is the first report of a single mammalian nu-
clear protein binding site that can function as a cell lineage-
specific transcriptional activator and repressor, and, as such,
suggests a novel mechanism for positively and negatively
regulating mammalian gene expression from a single tran-
scriptional enhancer element that is composed of multiple
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line,clone13, andthechronic myelogenous leukemia cell line K562
were grownin RPMI 1640 medium supplemented with 10% FCS




The pSPCAT plasmid containing the minimalSV40
promoter immediately 5' of thebacterial chloramphenicol acetyl
transferase (CAT) gene, and the pSPI1CAT plasmid which is
pSPCAT that contains the 4F2 heavy chain (4F2HC) enhancer 5'
of theminimal SV40 promoter have been described previously (9,
10) as have the pRSVCAT (11) and p4F2-589CAT (12) plasmids
in which CAT transcription is under thecontrol of the Rous sar-
coma virus long terminal repeat (LTR) and 4F2HC promoters,
respectively. ThepSPcwnhCAT plasmid which is pSPCAT that con-
tains the 116-bp BstXI/Dral human TCR-a enhancer fragment
3' of the CAT gene has also been described previously (7). The
promoterless pCATBasic plasmid was obtained from Promega-
Biotec (Madison, WI).
Synthetic Oligonucleotides and In Vitro Mutagenesis.
￿
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Figure 1.
￿
TheTa2 nuclear protein binding site of the human TCRa enhancer can function as both a transcriptional activatorand repressor. (A)
A schematic representation of the 116-bp minimal human TCRa transcriptional enhancer (7). The nucleotide sequences of the previously described
(7) Toil and Ta2 nuclear protein binding sites are shown above and below the map, respectively. The CRE within the Tal binding site is boxed
and labeled. Thesequence of a mutant Ta2 oligonucleotide (mTa2) that failsto bind nuclearproteins (8) is shown in the bottom line of the panel.
Synthetic Ta2 and mTa2 oligonucleotides corresponding to the sequences shown were synthesized with BamHI and Bg111 overhanging ends, and
used in thefunctional studies describedin CandDbelow. (B) Theeffects of mutations of theTa2 binding site on theactivity oftheTCR-aenhancer.
The wild-type TCR-a enhancer or a mutant enhancer (M) containing 11 nucleotide substitutions in the TO binding site (mTa2, A above) were
cloned into the BamHI site 3' of the minimal SV40 promotor/CAT cassette in the pSPCAT vector (9) and 10-,Ug of each of the resulting plasmids
along with 2 Ag of the pRSV#gal reference plasmid were transfected into humanJurkat T cells. The data are displayed as CAT activities relative
to that produced by theplasmid containing the wild-type TCR-aenhancer that resulted in 34% acetylation. (C)Theeffects of theTa2 nuclearprotein
binding site on transcription from theminimal SV40 promoter and4F2HC enhancer. Twocopies of synthetic oligonucleotides corresponding to the
wild-type (Ta2) or mutant (mTa2) Ta2binding sites (see A above) or three copies of the T05 nuclear protein binding site of the human TCR-O
enhancer (TAGAACTTCAGAGGGGAGGG) were cloned into the BamH1 site 3' of the minimal SV40 promoter and the 500 by 4F2HC enhancer
(4F2 Enh) in the pSPI1CAT plasmid (10). 10 ug ofeach of theresulting plasmids along with 2 legof the pRSV#gal plasmid was transfected into Jurkat
Tcells and CAT, andS-galactosidase activities were determined as describedin Materials and Methods. The data aredisplayedas CAT activities relative
to that produced by the pSP11CAT plasmid that produced 3% acetylation. (D) The effects of position on the transcriptional repressor function of
the Ta2 nuclear protein binding site. Four copies of the synthetic TO oligonucleotide (see A) were cloned into the BamHI site 3' of the 4F2HC
enhancer and minimal SV40 promoter/CAT gene or the Sacl site 5' of the 4F2HC enhancer and SV40 promoter/CAT gene in pSP11CAT, and 10
ug of the resulting plasmids along with 2 Rg ofthepRSVfgal plasmid were transfected into Jurkat cells. Thedata areshownas CAT activities relative
to those produced by the pSPIlCAT control plasmid that produced 7% acetylation.
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￿
Nuclear Protein Binding Site Functions as Transcriptional Activator or RepressorTal and Ta2 nuclear protein binding sites, and a mutant Ta2
nuclearprotein binding site (rnTce2, see Fig. 1 A) were synthesized
with BamHI/BgIII overhanging ends on a DNA synthesizer (model
380B; Applied Biosystems, Foster City, CA), and annealed before
cloning into the pSPCAT, pSPI1CAT, p4F2CAT, and pRSVCAT
plasmids. Thecopy number cloned into each plasmid was confirmed
by dideoxyDNA sequence analysis. A minimal human TCR-at en-
hancer containing 11 nucleotide substitutions within the Tact nu-
clear protein binding site (see Fig. 1 A) was produced by oligo-
nucleotide-mediated gapped heteroduplex mutagenesis as described
previously (10) and verified by dideoxy sequence analysis.
Transfections and CAT Assays.
￿
Jurkat, K562, and clone 13 cells
were transfected using a modification ofthe DEAF-dextranmethod
as described previously(7). Peer cells were transfected by electropo-
ration (7). To control for differences in transfection efficiencies, all
transfections contained 2 ttg of the pRSVOgal reference plasmid.
Cellswere harvested 48 h aftertransfection, and cell extracts nor-
malized for protein content using a commercially available kit (Bio-
rad, Richmond, CA) were assayed for both 0-galactosidase and
CAT activities as described previously (7).
Results
The Ta2 NuclearProtein Binding Site CanFunction as a Tran-
scriptional ActivatorandRepressor. To determine whether the
Toil and Ta2 binding sites by themselves were necessary,
or sufficient for TCR-a enhancer activity, two types of ex-
periments were performed. First, the Tat and Ta2 binding
sites were mutated so as to abolish nuclear protein binding
as assayed by electrophoretic mobility shift analyses. Muta-
tion or deletion of either the Toil (8) or Ta2 (reference 8,
and Fig. 1 B) binding sites essentially abolished enhancer ac-
tivity, indicating that both the Tat and Ta2 sites function
as transcriptional activator elements in the context of the
TCRa enhancer. In a reciprocal set ofexperiments, synthetic
oligonucleotides corresponding to the Toil and Ta2 binding
sites were cloned into the BamHI site of the pSPCAT reporter
plasmid (9), 3' of the minimal SV40 promoter and the bac-
terial CAT gene, and transfected into Jurkat TCRa/a+ T
cells. In the absence of stimulation ofprotein kinase A, two
copies of the Tat oligonucleotide had no significant effect
on CAT transcription (data not shown). Surprisingly, how-
ever, two copies of'the Ta2 oligonucleotide appeared to com-
pletely suppress CAT transcription (data not shown), although
the magnitude of this repression was difficult to quantitate
because of the low basal levels of transcription from the min-
imal SV40 promoter in thisplasmid. To better assess the nega-
tive regulatory activity of the Ta2 element, two copies of
the synthetic Ta2 oligonucleotide were cloned into the BamHI
site ofthe pSPHCAT vector (10) that contains the previously
described 4F2 heavy chain (4F2HC) enhancer 5' of the min-
imal SV40 promoter/CAT cassette (Fig. 1 C). This plasmid
was chosen as a reporter for Ta2 transcriptional repressor
activity because we have demonstrated previously that the
4F2HC enhancer is highly active in a wide variety of lym-
phoid and non-lymphoid human tumor cell lines (10). As
shown in Fig. 1 C, two copies ofthe Ta2 binding site resulted
in an 84% reduction in CAT activity in Jurkat cells as com-




specific for the Ta2 oligonucleotide because it was not ob-
served when two copies of a mutant Ta2 (mTa2) oligonu-
cleotide (Fig. 1 A) that fails to bind T cell-specific nuclear
proteins (8), or three copies ofthe T05 oligonucleotide that
corresponds to a nuclear protein binding site from the human
TCR-O transcriptional enhancer (13) were cloned into the
BarnHI site of pSPI1CAT (Fig. 1 C).
Ta2 Transcriptional Repressor Activity Is Position Indepen-
dent. We have demonstrated previously (7) that the tran-
scriptional activator properties of the TCRa enhancer are
independent ofthe position and orientation of the enhancer
element. To determine whether the transcriptional repressor
activity of the Ta2 binding site was similarly position inde-
pendent, we compared the activity of four copies of Ta2
cloned 5' of the 4F2HC enhancer and minimal SV40 pro-
moter/CAT cassette to the activity of the same sites cloned
3' of the CAT gene in this vector (Fig. 1 D). The ability
of Ta2 to repress transcription was slightly reduced when
the Ta2 sites were cloned 5' of the promoter and enhancer
as compared with 3' of the CAT gene (66% reduction vs.
92% reduction). Nevertheless, the transcriptional repressor
effect was relatively independent of the position of the Ta2
binding sites.
Ta2 Represses Transcription from Multiple Heterologous
Promoters and Enhances. Previous studies (7) have demon-
strated that the TCRa enhancer is able to confer T
cell-specific transcriptional enhancement upon both a Va pro-
moter and several heterologous promoters. To determine
whether the Ta2 element alone was capable of repressing
transcription from multiple distinct promoter and enhancer
elements in Jurkat cells, four copies of a synthetic Ta2 oli-
gonucleotide were cloned 3' ofCAT reporter genesthat were
under the control of the Rous sarcoma virus (RSV) pro-
moter/enhancer, or the 4F2 heavy chain (4F2HC) promoter,
a G + C rich "housekeeping" promoter that lacks a TATA
box and initiator sequence (14), but contains multiple SP1
binding sites (15). These plasmids were transfected into human
Jurkat T cells, and the resulting CAT activities were com-
pared with those produced by control plasmids lacking the
Ta2 binding sites (Fig. 2). Four copies ofTa2 significantly
reduced transcription from each of these promoter/enhancer
combinations (>90% reduction), demonstrating that the
transcriptional repressor activity of Ta2 was not unique to
the SV40 promoter or to the 4F2HC enhancer, and that this
activity was not restricted to TATAcontaining promoters.
In additional experiments, four copies of the Ta2 binding
site also inhibited transcription from a minimal SV40 pro-
moter/TCRa enhancer by >98% (data not shown) .
The TranscriptionalRepressorActivity ofT62 Is TCell-specific
The TCRa enhancer is active only in TCRa/a+ T cells
(7), and previous studies have demonstrated that the Ta2
enhancer motifbindsat least two nuclear protein complexes,
one of which is present only in TCR-a/(3+ and TCR-y/S+
T cells (8). To determine whether the transcriptional repressor
activity of the Ta2 binding site was restricted to a specific
cell lineage, plasmids containing four copies of the Ta2
binding site cloned 3' ofthe 4F2HC enhancer and SV40 pro-
moter/CAT cassette were transfected into Jurkat TCRa/a+Figure 2.
￿
The Ta2 element can repress transcription from multiple heterologous promoter and enhancer elements. Four copies of a synthetic Tat
oligonucleotide (see Fig. 1 A) were cloned into the BamHI site 3' of the 4F2HC enhancer and minimal SV40 promoter/CAT cassette in PSPIICAT
(10) (A), the RSV LTR/CAT cassette in pRSVCAT (11) (B), or the 589-bp 4F2HC promoter (4F2 Pr)/CAT cassette in p4F2-589CAT (12) (C). 10 fcg
ofeach ofthe resulting plasmids along with 2 ug of the pRSV,6gal reference plasmid were transfected into Jurkat T cells, and CAT and fl-galactosidase
activities were determined as described in Materials and Methods. The data are displayed as CAT activities relative to those produced in transfections
with the appropriate control plasmids lacking the Ta2 elements.
Figure 3.
￿
The Ta2 element functions as a T cell-specific transcriptional repressor. 10 Etg of the pSPCAT, pSP11CAT, and pSPIICAT(Ta2)4 plasmids
shown schematically in the top panel along with 2 j+g of the pRSVsgal reference plasmid were transfected into Jurkat TCR-a/g' T cells, Peer-,y/6'
T cells, clone 13 EBVtransformed B cells, and K562 chronic myelogenous leukemiacells, and cell extracts were assayed for both CAT and ,B-galactosidase
activities as described in Materials and Methods. The data are displayed as CAT activities relative,to those produced by the pSPHCAT plasmid that
were 7, 8, 3, and 6% total acetylation, respectively, in the Jurkat, Peer, clone 13, and K562 cell lines.
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￿
Nuclear Protein Binding Site Functions as Transcriptional Activator or RepressorT cells, Peer TCR-,y/6' T cells, clone 13 EBVtransformed
B cells, and K562 chronic myelogenous leukemia cells, and
their activities were compared with those produced by the
same plasmids lacking the Ta2 binding sites (Fig . 3) .
Significant repression of transcription (92 and 98% reduc-
tions, respectively) was observed in the Jurkat and Peer T
cells. In contrast, no repression was observed in either the
K562 or clone 13 cells. A similar pattern of T cell-specific
repression was observed after transfection of a plasmid con-
taining four copies of the Ta2 binding site cloned 3' of an
RSV promoter/enhancer/CAT cassette (data not shown) .
Taken together, these results demonstrated that the transcrip-
tional repressor activity oftheTa2 element is T cell specific,
and suggested that this activitymaybe mediated by the ability
of this element to bind one or more T cell-specific nuclear
proteins.
The Transcriptional Repressor Activity ofTa2 is a cis-acting
Eject and Is Proportional to the Number ofCopies of the Ta2
Binding Site . The transcriptional activator function ofmany
enhancer elements is directly proportional to the number of
copies of these elements that are present in a given reporter
plasmid . To determine whether the transcriptional repressor
activity of the Ta2 element was similarly proportional to
its copy number, one to four copies of the synthetic Ta2
oligonucleotide were cloned into the BamHI site 3' of the
RSV promoter/enhancer/CAT cassette, and these plasmids




meats demonstrated that the transcriptional repressor activity
of the Ta2 element was directly proportional to the number
of copies ofTa2 with 94% repression of transcription ob-
served with four copies of Ta2 .
One mechanism that could account for the transcriptional
repressor activity of the Ta2 element is that this element
is able to compete efficiently for the binding of generalized
transcription factors, thereby causing an overall decrease in
transcription in the transfected cells. To test this possibility,
all transfections contained 2 pg of the pRSV#gal reference
plasmid in which (3-galactosidase gene expression is under
the control of theRSV promoter/enhancer. As shown in Fig.
4, 0-galactosidase activity was essentially identical in all of
the transfections, regardless of the number of copies ofTa2
contained within the CAT reporter plasmid . Similar results
were obtained in all of the transfections shown in Figs . 1-3
(data not shown) . Thus, the transcriptional repressor activity
ofTa2 is a cis-acting effect, and is not simply the result of
generalized decreases in transcriptional activity in cells trans-
fected with Ta2-containing plasmids .
A second mechanism that could account for the apparent
transcriptional repressor activity of the Ta2 binding site is
that this enhancer element, when polymerized, can also func-
tion as a promoter, thereby artifactually reducingCAT tran-
scription in our transient transfection assays by a mechanism
of promoter interference. To rule out this possibility, four
copies of the Ta2 binding site were cloned in both orienta-
Figure 4.
￿
The effect of copy number on
the transcriptional repressor activity of the
Ta2 element. One to four copies ofthe syn-
thetic Ta2 oligonucleotide werecloned into
the BamHl site ofpRSVCAT (see Fig. 2 B)
3' oftheRSV LTR/CAT cassette and 10 Ag
of the resulting plasmids, along with 2 Eag
of the pRSV/Igal reference plasmid, were
transfected intoJurkatT cells. CAT (solidban)
and 0-galactosidase (slashed bars) activities
weredetermined as describedinMaterials and
Methods . The CAT activities were normal-
ized to that produced by thepRSVCAT con-
trol plasmid that produced 27% total acety-
lation .tions immediately 5' ofa promoterless CAT gene in the pCAT-
Basic plasmid, and the resulting plasmids were transfected
into Jurkat T cells (Fig.5) . Four copies of the Ta2 binding
site had no effect on CAT activity as compared with the
promoterless pCATBasic control plasmid . Thus, the element
does not display significant promoter activity in this system .
Discussion
The studies described in this report have demonstrated that
a single nuclear protein binding site from thehumanTCR-a
enhancer can function as both aT cell-specific transcriptional
activator and repressor, dependingupon the context in which
this element is located . The finding that Ta2-mediated tran-
scriptional repressor activity is T cell specific, when taken
together with previous observations (8) that the Ta2 ele-
ment binds at least one T cell-specific nuclear protein com-
plex, suggests that nuclear protein binding may be respon-
sible for the Tc12 transcriptional repressor activity. This
hypothesis is supported by the finding that Tc12 mutations
that abolished nuclear protein binding also abolished tran-
scriptional repressor activity. The fact that the Ta2 element
is able to repress transcription from multiple, apparently un-
related, enhancer elements suggests that repression may be
mediated by direct effects ofTa2 and its cognate nuclear pro-
teins on the ability of the transcription complex to form at
the promoter, or to initiate transcription once formed . These
effects apparently do not require either a functional TATA
box, or an initiator sequence in that Tc12 significantly repressed
transcription from the 4F2HC promoter that lacks these
elements.
Previous studies in other systems have demonstrated that
a single nuclear protein can either activate or repress tran-
scription by binding to distinct cis-acting regulatory elements
(16, 17) . In addition, one previous report (18) has demon-
strated that two different sequence motifs that are involved
in silencing transcription of the yeast silent mating type loci
can activate transcription when linked to heterologous
promoters. To our knowledge, however, this is the first re-
port of a single cis-acting element that can both activate and
repress transcription in a tissue-specific fashion in a mam-
malian system . Our results raise two questions concerning
Figure 5 .
￿
lack ofpromoter activity ofthe Ta2 element . Four
copies of the synthetic Tc 12 oligonucleotide were cloned in both
orientationsinto the Hindlil site immediately 5' of theCAT gene
in the promoterless pCATBasic plasmid. 10 Pg of the resulting
plasmids along with 2 ug of the pFtSVsgal reference plasmid
were transfected into Jurkat T cells. The data are shown as CAT
activities relative to that produced by the promoterless pCAT
Basic control plasmid (which produced 0.17% acetylation) fol-
lowing correction for differences in transfection efficiencies . The
pSPaxnhCAT plasmid was included as a positive control in a par-
allel transfection and produced 24% total acetylation (data not
shown) .
the general phenomena of transcriptional repression and ac-
tivation . First, what is the molecular mechanism that accounts
for the bifunctional transcriptional regulatory potential of
the Ta2 element inT cells? And second, what is the physio-
logic significance of these findings in terms of developmen-
tally regulated gene expression?
One mechanism that could account for the positive and
negative regulatory potential of the Tc12 nuclear protein
binding site is that different sets of proteins are able to bind
to this site, depending upon the context in which it is lo-
cated. Thus, one or more transcriptional activator proteins
might bind to Ta2 in the context of the wild-type TCR
a enhancer, while a distinct set of transcriptional repressor
proteins might bind preferentially to theTa2 element alone .
There is an equally tenable, and perhaps more interesting pos-
sibility that could account both for the ability of a single
nuclear protein to activate and repress transcription when
bound to different cis-acting sequence elements, and for the
ability of a single cis-acting sequence element to mediate both
transcriptional activation and repression . Specificially, some
transcriptional regulatory proteins might be capable ofbinding
to cis-acting regulatory sequences with two different confor-
mations, one of which mediates transcriptional activation,
and the other of which causes transcriptional repression . In-
terconversions between these two conformations could be
caused either by the binding of such bifunctional regulatory
proteins to different sequence motifs, or alternatively, by in-
teractions of such bifunctional proteins with additional pro-
teins bound to adjacent cis-acting elements. Thus, for example,
interactions between proteins bound to the Ta2 and Tail
sites of the TCRa enhancer might result in a Tc12 confor-
mation that activates transcription, while binding ofthe same
proteins to Ta2 elements alone might result in a transcrip-
tional repressor conformation. Our ability to distinguish be-
tween these different potential mechanisms requires a better
understanding of the Tat and Tc12 binding proteins .
Finally, it is worth noting that, regardless of the molec-
ular mechanisms that account for the dual transcriptional
regulatory activities of the Ta2 element, our results suggest
that a transcriptional enhancer that is composed of multiple
nuclear protein binding sites can be converted to a transcrip-
tional silencer by altering the levels ofexpression ofthe rele-
vant transcriptional activator proteins. Thus, for example, the
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￿
Nuclear Protein Binding Site Functions as Transcriptional Activator or Repressoractivity of the human TCRa enhancer could be changed
from that of a transcriptional activator to that of a transcrip-
tional repressor by reductions in the levels of expression or
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